Back to top

Research Daily

Friday, November 25 2016

Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Microsoft (MSFT) and Priceline (PCLN).

Pfizer’s shares have been showing some weakness recently. Pfizer’s third quarter results missed expectations for both sales and earnings. But the analyst emphasizes that Pfizer is strengthening its product portfolio as well as pipeline through acquisitions and licensing deals. The Sep 2016 acquisition of Medivation has strengthened Pfizer’s cancer franchise.

Meanwhile, new products like Ibrance should do well and drive revenues. However, headwinds remain in the form of genericization, pricing pressure and rising competition, which will continue to hamper top-line growth. (You can read the full research report on Pfizer here.)

Microsoft’s shares have gained more than 8% this year. Microsoft reported impressive first-quarter 2017 results driven by strong cloud growth. The analyst likes its continuing enterprise strength, benefits from the Office 365 subscription model, strong growth prospects of Azure and promising new products.

Additionally, the expansion of Microsoft HoloLens in 6 new markets will improve the company's position in the augmented and virtual reality space. Further, the anticipated completion of the LinkedIn acquisition will boost Microsoft's presence in the social media market. However, execution and foreign exchange risks remain despite its cloud focus. (You can read the full research report on Microsoft here.)

Priceline shares have surged, increasing by more than 19% year-to-date. Priceline reported strong third quarter results. Both agency and merchant businesses showed strong momentum. The analyst likes Priceline’s strong position in international markets, good execution, prudent marketing strategy and strong financial position.

The secular growth trend in the online travel booking market and growth opportunities in the domestic market are other positives. At the same time, weaker ADRs, macro headwinds, increasing advertising spend and occupancy tax-related litigation remain overhangs. (You can read the full research report on Priceline here.)

Other noteworthy reports we are featuring today include General Electric (GE), Expedia (EXPE) and United Continental (UAL).

Today's Long-Term Buys & Sells
Today you can gain access to the best long-term trades unearthed by Zacks Research. These moves have double and triple-digit profit potential and are rarely available to the public. Starting now, you can look inside our stocks under $10, home run and value stock portfolios, plus more. Want a peek at this private information? Click here >>

Mark Vickery

Senior Editor

Note: If you want an email notification each time Zacks Director of Research Sheraz Mian publishes a new article, please click here>>>

Featured Reports

Campbell (CPB) Tops Q1 Earnings

The Zacks analyst believes solid Q1 earnings were backed by cost savings efforts. Campbell retained its outlook but a weak show by Campbell Fresh hurt organic sales.

New Upgrades

New Downgrades